Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 4Phase 1 4Phase NA 1Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1

Status

Recruiting 3Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Dermatologic 1

Conditions

Pancreatic Neoplasms 1Neoplasms, Basal Cell 1Localized Pancreatic Adenocarcinoma 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 210Cyclophosphamide 122Nivolumab 109Carboplatin 92fludarabine 81Gemcitabine 77Specimen Handling 74Bevacizumab 72venetoclax 70Injections 70Magnetic Resonance Spectroscopy 67Dexamethasone 66Paclitaxel 64Biopsy 59atezolizumab 56Cisplatin 53Ipilimumab 50Temozolomide 45Docetaxel 42Azacitidine 42Pemetrexed 41Lenalidomide 41Oxaliplatin 40Rituximab 39Radiotherapy 39Fluorouracil 39Cetuximab 37durvalumab 36Cytarabine 36Capecitabine 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × folfirinox × 1 year × Clear all
NCT06483555 2026-04-23

PANGEA

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Recruiting
104 enrolled
DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT03828799 2026-02-27

FOLFIRINOX-R

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 1/2 Completed
13 enrolled 22 charts
Gastrointestinal

Colorectal Neoplasms

NCT06384560 2026-02-13

PREOPANC-5

Amsterdam UMC, location VUmc

Phase 1/2 Recruiting
66 enrolled
Gastrointestinal

Localized Pancreatic Adenocarcinoma

NCT05482893 2025-11-04

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Phanes Therapeutics

Phase 1/2 Recruiting
258 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡